Trial Profile
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- 26 Nov 2021 Planned initiation date changed from 31 May 2020 to 1 Dec 2022.
- 26 Nov 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 14 Sep 2020 Status changed from not yet recruiting to recruiting.